Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

[1]  J. Crowley,et al.  International prognostic scoring system for Waldenström s Macroglobulinemia Short title: Prognostic index for Waldenström Macroglobulinemia , 2017 .

[2]  E. Kimby,et al.  Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial , 2015, The Lancet.

[3]  M. Dyer,et al.  Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study , 2015, Haematologica.

[4]  M. Czuczman,et al.  Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin’s lymphoma , 2015, Annals of Hematology.

[5]  A. Hagenbeek,et al.  Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis , 2014, Journal of clinical pharmacology.

[6]  M. Gertz,et al.  Hodgkin lymphoma: 2012 update on diagnosis, risk‐stratification, and management , 2012, American journal of hematology.

[7]  M. Gertz.  Waldenström macroglobulinemia , 2012, Hematology.

[8]  M. Dyer,et al.  Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Treon.  How I treat Waldenström macroglobulinemia. , 2009, Blood.

[10]  Paul W. H. I. Parren,et al.  Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX1 , 2009, The Journal of Immunology.

[11]  J. Tamburini,et al.  Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. , 2009, Clinical lymphoma & myeloma.

[12]  S. Treon,et al.  Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Pasmantier,et al.  Thalidomide and rituximab in Waldenstrom macroglobulinemia. , 2004, Blood.

[14]  P. Parren,et al.  The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201 , 2006, The Journal of Immunology.

[15]  E. Kimby,et al.  Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. , 2006, Clinical lymphoma & myeloma.

[16]  Evangelia Dimitriadou,et al.  Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders. , 2005, Clinical lymphoma.

[17]  M. Rue,et al.  Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia , 2004, Cancer.

[18]  M. Dimopoulos,et al.  Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression , 2004, Leukemia & lymphoma.

[19]  M. Rue,et al.  Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98) , 2004, Leukemia & lymphoma.

[20]  S. Treon,et al.  Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  P. Parren,et al.  Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. , 2004, Blood.

[22]  I. Ghobrial,et al.  Waldenström macroglobulinemia , 2004, Current treatment options in oncology.

[23]  R. Owen.  Developing diagnostic criteria in Waldenstrom's macroglobulinemia. , 2003, Seminars in oncology.

[24]  A. Pestronk,et al.  Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[25]  J. Byrd,et al.  Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[26]  M. Dimopoulos,et al.  Treatment of Waldenström's macroglobulinemia with rituximab. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Coiffier,et al.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Byrd,et al.  Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.